|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation
This is a single arm, open-label, multi-center, phase 1-2a study to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose and the safety of CARCIK-CD19 in adult and pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
100 Clinical Results associated with Fondazione Matilde Tettamanti e Menotti de March
0 Patents (Medical) associated with Fondazione Matilde Tettamanti e Menotti de March
100 Deals associated with Fondazione Matilde Tettamanti e Menotti de March
100 Translational Medicine associated with Fondazione Matilde Tettamanti e Menotti de March